Abstract
While there have been legitimate concerns in the past regarding the use of anthelmintics for the management of neuroangiostrongyliasis (rat lungworm disease), recent studies demonstrate that they can be considered safe and efficacious, particularly albendazole, which is regarded as the choice anthelmintic for its management. However, physician hesitancy to prescribe, as well as problems of availability persist, at least in Hawaii, which is considered the epicenter of this disease in the US. As a result, many patients suffer a diminished quality of life or even death. Here, we discuss recent studies that provide insights into new treatments and preventative interventions, which can be more rigorously used for the management of neuroangiostrongyliasis. In summary, results from recent studies suggest that albendazole and avermectins are beneficial for post-exposure management, pyrantel pamoate is beneficial as a post-exposure prophylactic, and levamisole is deserving of further study for the treatment of neuroangiostrongyliasis.
Subject
Infectious Diseases,Microbiology (medical),General Immunology and Microbiology,Molecular Biology,Immunology and Allergy
Reference44 articles.
1. Angiostrongylus cantonensis eosinophilic meningitis;Pien;Int. J. Infect. Dis.,1999
2. Human angiostrongyliasis;Wang;Lancet Infect. Dis.,2008
3. Neuroangiostrongyliasis: The “Subarachnoid Phase” and Its Implications for Anthelminthic Therapy;Prociv;Am. J. Trop. Med. Hyg.,2018
4. Corticosteroid treatment reduces headache in eosinophilic meningitis: a systematic review;Khamsai;Drug Target Insights,2021
5. Clinical studies on angiostrongyliasis cantonensis among children in Taiwan;Hwang;Southeast Asian J. Trop. Med. Public Health,1991
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献